Personalized medicine and proteomics: Lessons from non-small cell lung cancer

被引:38
作者
Marko-Varga, Gyorgy
Ogiwara, Atsushi
Nishimura, Toshihide
Kawamura, Takeshi
Fujii, Kiyonaga
Kawakami, Takao
Kyono, Yutaka
Tu, Hsiao-Kun
Anyoji, Hisae
Kanazawa, Mitsuhiro
Akimoto, Shingo
Hirano, Takashi
Tsuboi, Masahiro
Nishio, Kazuto
Hada, Shuji
Jiang, Haiyi
Fukuoka, Masahiro
Nakata, Kouichiro
Nishiwaki, Yutaka
Kunito, Hideo
Peers, Ian S.
Harbron, Chris G.
South, Marie C.
Higenbottam, Tim
Nyberg, Fredrik [13 ]
Kudoh, Shoji
Kato, Harubumi
机构
[1] AstraZeneca R&D, SE-22187 Lund, Sweden
[2] Tokyo Med Coll, Clin Proteome Ctr, Shinjuku Ku, Tokyo 1630217, Japan
[3] Med ProteoScope Co Ltd, Shinjuku Ku, Tokyo 1630217, Japan
[4] Tokyo Med Univ, Dept Surg, Shinjuku Ku, Tokyo 1600023, Japan
[5] AstraZeneca KK, Res & Dev, Clin Div, Kita Ku, Osaka 5310076, Japan
[6] AstraZeneca KK, Res & Dev, Dept Clin Sci, Kita Ku, Osaka 5310076, Japan
[7] Kinki Univ, Sch Med, Dept Med Oncol, Osaka 5898511, Japan
[8] Toho Univ, Sch Med, Dept Resp Dis, Ota Ku, Tokyo 1438541, Japan
[9] Natl Canc Ctr Hosp E, Dept Thorac Oncol, Chiba 2778577, Japan
[10] AstraZeneca R&D Alderley Pk, Macclesfield, Cheshire, England
[11] AstraZeneca R&D Charnwood, Leicester LE11 5RH, Leics, England
[12] Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England
[13] AstraZeneca R&D, SE-43183 Molndal, Sweden
[14] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden
[15] Nippon Med Sch, Dept Internal Med 4, Bunkyo Ku, Tokyo 1138603, Japan
关键词
personalized medicine; gefitinib; therapy; interstitial lung disease; non-small cell lung cancer; biomarkers; predictive test; mass spectrometry; statistical analysis; proteomics;
D O I
10.1021/pr070046s
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Personalized medicine allows the selection of treatments best suited to an individual patient and disease phenotype. To implement personalized medicine, effective tests predictive of response to treatment or susceptibility to adverse events are needed, and to develop a personalized medicine test, both high quality samples and reliable data are required. We review key features of state-of-the-art proteomic profiling and introduce further analytic developments to build a proteomic toolkit for use in personalized medicine approaches. The combination of novel analytical approaches in proteomic data generation, alignment and comparison permit translation of identified biomarkers into practical assays. We further propose an expanded statistical analysis to understand the sources of variability between individuals in terms of both protein expression and clinical variables and utilize this understanding in a predictive test.
引用
收藏
页码:2925 / 2935
页数:11
相关论文
共 85 条
[1]   Mass spectrometry-based proteomics [J].
Aebersold, R ;
Mann, M .
NATURE, 2003, 422 (6928) :198-207
[2]  
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, Am J Respir Crit Care Med, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]
[3]   A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: Support vector machine classification of peptide MS/MS spectra and SEQUEST scores [J].
Anderson, DC ;
Li, WQ ;
Payan, DG ;
Noble, WS .
JOURNAL OF PROTEOME RESEARCH, 2003, 2 (02) :137-146
[4]  
ANDERSON NG, 1982, CLIN CHEM, V28, P739
[5]  
Anderson NG, 2001, PROTEOMICS, V1, P3, DOI 10.1002/1615-9861(200101)1:1<3::AID-PROT3>3.0.CO
[6]  
2-T
[7]   The human plasma proteome - History, character, and diagnostic prospects [J].
Anderson, NL ;
Anderson, NG .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) :845-867
[8]   The human plasma proteome - A nonredundant list developed by combination of four separate sources [J].
Anderson, NL ;
Polanski, M ;
Pieper, R ;
Gatlin, T ;
Tirumalai, RS ;
Conrads, TP ;
Veenstra, TD ;
Adkins, JN ;
Pounds, JG ;
Fagan, R ;
Lobley, A .
MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (04) :311-326
[9]   Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer [J].
Araki, J ;
Okamoto, I ;
Suto, R ;
Ichikawa, Y ;
Sasaki, J .
LUNG CANCER, 2005, 48 (01) :141-144
[10]  
ASADA K, 1992, Japanese Journal of Chest Diseases, V51, P214